Approval · Notice of Compliance 22871 · 2019
INTERCEPTOR PLUS: Notice of Compliance 22871
Issued November 7, 2019
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 22871
- Date
- November 7, 2019
- Company
- Elanco Canada LimitedGuelph, Ontario, Canada
- Product type
- Veterinary
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Alternate manufacturing site ¿ drug substance (Praziquantel)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| INTERCEPTOR PLUS | 02468344 | Marketed |
| INTERCEPTOR PLUS | 02468352 | Marketed |
| INTERCEPTOR PLUS | 02468360 | Marketed |
| INTERCEPTOR PLUS | 02468379 | Marketed |
Medicinal ingredients
- MILBEMYCIN OXIME 2.3 MG per TAB
- PRAZIQUANTEL 22.8 MG per TAB
- MILBEMYCIN OXIME 5.75 MG per TAB
- PRAZIQUANTEL 57 MG per TAB
- MILBEMYCIN OXIME 11.5 MG per TAB
- PRAZIQUANTEL 114 MG per TAB
- MILBEMYCIN OXIME 23 MG per TAB
- PRAZIQUANTEL 228 MG per TAB